Patient Guide to Support Services


Xtandi Support Solutions

Astellas Pharma’s Xtandi Support Solutions offers patient assistance services to eligible patients who are prescribed Xtandi (enza­lutamide) for the treatment of castration-resistant prostate cancer (CRPC) or for metastatic CRPC (Table).

Xtandi Support Solutions has several financial assistance programs for Xtandi, including the Xtandi Patient Savings Program for commercially insured patients, the Astellas Patient Assistance Program for uninsured and underinsured patients, and the Xtandi Quick Start+ Program for patients who experience delays in insurance coverage.

For patients with Medicare coverage with out-of-pocket costs, Xtandi Support Solutions can provide information about other resources that may be able to help.


Xtandi Patient Savings Program

This program is designed for patients who have private health insurance but who may not be able to pay their out-of-pocket costs. There are no income requirements. Patients are not eligible for the program if they have prescription drug coverage in part or in full from any state-funded or federally funded programs; there also are other rules and restrictions

Each medication refill will cost patients as little as $0 a month, and up to $25,000 annually.

Astellas Patient Assistance Program

This program is for patients without health insurance—although some Medicare Part D patients may be eligible—and provides Xtandi free to patients who meet certain criteria. Patients must meet the following eligibility guidelines:

  • Have been prescribed Xtandi for an FDA-approved indication
  • Are uninsured or have insurance that excludes coverage for Xtandi
  • Meet the program financial eligibility requirements
  • Have a verifiable shipping address within the United States.

Xtandi Quick Start+ Program

A free, 1-time, 14-day supply of Xtandi is offered to eligible patients who have a delay in obtaining approval for coverage of Xtandi by their insurance provider. The Xtandi Quick Start+ Program is for patients who are beginning to use Xtandi. Patients who are eligible for this program must:

  • Have prescription drug insurance
  • Be new to Xtandi therapy
  • Have experienced an insurance-­related access delay
  • Have been prescribed Xtandi for an FDA-approved indication.

Patients with Medicare Coverage

Medicare typically covers Xtandi capsules under the Medicare Part D prescription drug benefit. However, the patient’s cost-sharing may vary among Medicare plans.

For patients who need financial assistance, Xtandi Support Solutions can:

  • Help to determine what type of cost-sharing the patient has, such as a flat copayment or a percentage-based coinsurance
  • Evaluate the patient’s eligibility for Medicare Low-Income Subsidy (or “extra help”)
  • Provide information about other resources.

Application & Enrollment

To determine whether a patient qualifies for payment assistance, his or her healthcare provider should fill out the Patient Enrollment Form and fax it to 855-982-6341.

The provider can call Xtandi ­Support Solutions at 855-898-2634, or can access Astellas eService online to verify benefits and cost-sharing requirements and to obtain more information about assistance options.

The patient’s Social Security number is required to assess eligibility for the Astellas Patient Assistance Program.

On receipt of the Patient Enrollment Form, Xtandi Support Solutions performs the benefits verification, which evaluates the patient’s insurance coverage requirements for Xtandi, requirements for prior authorization, cost-sharing responsibility (including deductibles, coinsurance or copayment, and out-of-pocket maximums), and a list of specialty pharmacies that participate in the patient’s insurance coverage.

Xtandi Quick Start+ Program

A physician, pharmacy, or a member of Astellas Support Solutions staff can initiate the program after the prescriber completes the Quick Start+ portion of the Xtandi Support Solutions Patient Enrollment Form.

Table Astellas Oncology Drug

Patient support programs

Xtandi (enzalutamide)
Castration-resistant prostate cancer; metastatic castration-resistant prostate cancer

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: